- Home
- NSTS vs NRXP Comparison
NSTS vs NRXP Comparison
Compare NSTS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | NRXP |
|---|---|---|
| Founded | 1921 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | NRXP |
|---|---|---|
| Price | $11.62 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 5.6K | ★ 446.3K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $1.15 |
| 52 Week High | $13.32 | $6.01 |
Technical Indicators
Market Signals| Indicator | NSTS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 66.32 | 45.23 |
| Support Level | $11.14 | $2.22 |
| Resistance Level | $11.75 | $2.51 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 88.00 | 68.52 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.